• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无监督机器学习可改善新诊断多发性骨髓瘤的风险分层:西班牙骨髓瘤组的分析。

Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group.

机构信息

Hospital Clínico Universitario Santiago de Compostela, A Coruña, Spain.

Hospital Clínic, Institut d'investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.

出版信息

Blood Cancer J. 2022 Apr 25;12(4):76. doi: 10.1038/s41408-022-00647-z.

DOI:10.1038/s41408-022-00647-z
PMID:35468898
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9038663/
Abstract

The International Staging System (ISS) and the Revised International Staging System (R-ISS) are commonly used prognostic scores in multiple myeloma (MM). These methods have significant gaps, particularly among intermediate-risk groups. The aim of this study was to improve risk stratification in newly diagnosed MM patients using data from three different trials developed by the Spanish Myeloma Group. For this, we applied an unsupervised machine learning clusterization technique on a set of clinical, biochemical and cytogenetic variables, and we identified two novel clusters of patients with significantly different survival. The prognostic precision of this clusterization was superior to those of ISS and R-ISS scores, and appeared to be particularly useful to improve risk stratification among R-ISS 2 patients. Additionally, patients assigned to the low-risk cluster in the GEM05 over 65 years trial had a significant survival benefit when treated with VMP as compared with VTD. In conclusion, we describe a simple prognostic model for newly diagnosed MM whose predictions are independent of the ISS and R-ISS scores. Notably, the model is particularly useful in order to re-classify R-ISS score 2 patients in 2 different prognostic subgroups. The combination of ISS, R-ISS and unsupervised machine learning clusterization brings a promising approximation to improve MM risk stratification.

摘要

国际分期系统(ISS)和修订的国际分期系统(R-ISS)是多发性骨髓瘤(MM)中常用的预后评分。这些方法存在显著的差距,特别是在中危组中。本研究的目的是使用西班牙骨髓瘤组开发的三项不同试验的数据来改善新诊断的 MM 患者的风险分层。为此,我们在一组临床、生化和细胞遗传学变量上应用了无监督机器学习聚类技术,并确定了两组具有显著不同生存的新型患者群。这种聚类的预后精度优于 ISS 和 R-ISS 评分,并且似乎特别有助于改善 R-ISS 2 患者的风险分层。此外,在 GEM05 年龄大于 65 岁的试验中,与 VTD 相比,接受 VMP 治疗的低危组患者的生存获益显著。总之,我们描述了一种用于新诊断 MM 的简单预后模型,其预测结果独立于 ISS 和 R-ISS 评分。值得注意的是,该模型特别有助于将 R-ISS 评分 2 的患者重新分类为 2 个不同的预后亚组。ISS、R-ISS 和无监督机器学习聚类的结合为改善 MM 风险分层带来了有前途的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b82/9038663/c208aa45db79/41408_2022_647_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b82/9038663/d84e6d4c07b5/41408_2022_647_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b82/9038663/b7a9a8bc0940/41408_2022_647_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b82/9038663/0c88d4a2cd37/41408_2022_647_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b82/9038663/c208aa45db79/41408_2022_647_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b82/9038663/d84e6d4c07b5/41408_2022_647_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b82/9038663/b7a9a8bc0940/41408_2022_647_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b82/9038663/0c88d4a2cd37/41408_2022_647_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b82/9038663/c208aa45db79/41408_2022_647_Fig4_HTML.jpg

相似文献

1
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group.无监督机器学习可改善新诊断多发性骨髓瘤的风险分层:西班牙骨髓瘤组的分析。
Blood Cancer J. 2022 Apr 25;12(4):76. doi: 10.1038/s41408-022-00647-z.
2
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.修订版国际分期系统(R2-ISS)在多发性骨髓瘤整体生存中的应用:Harmony 项目下欧洲骨髓瘤网络(EMN)的报告。
J Clin Oncol. 2022 Oct 10;40(29):3406-3418. doi: 10.1200/JCO.21.02614. Epub 2022 May 23.
3
The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.与经典国际分期系统相比,修订后的国际分期系统能更好地区分移植不合格的多发性骨髓瘤患者中的风险组。
Oncol Res Treat. 2017;40(10):616-620. doi: 10.1159/000478935. Epub 2017 Sep 19.
4
[Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].[根据Mayo骨髓瘤分层及修订的国际分期系统分析血清游离轻链κ/λ比值和免疫球蛋白重/轻链对在多发性骨髓瘤分层中的作用]
Vnitr Lek. 2016 Apr;62(4):269-80.
5
Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.新型药物时代多发性骨髓瘤预后分期系统的评估。
Hematol Oncol. 2022 Apr;40(2):212-222. doi: 10.1002/hon.2955. Epub 2021 Dec 12.
6
The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma.循环浆细胞的检测可能会改善新诊断多发性骨髓瘤患者的修订国际分期系统(R-ISS)风险分层。
Br J Haematol. 2021 May;193(3):542-550. doi: 10.1111/bjh.17118. Epub 2021 Apr 1.
7
The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor-based regimens as induction treatment: A real-world analysis.国际分期系统第二版在接受免疫调节药物或蛋白酶体抑制剂为基础方案诱导治疗的多发性骨髓瘤患者中的适用性:一项真实世界分析。
Hematol Oncol. 2023 Feb;41(1):139-146. doi: 10.1002/hon.3090. Epub 2022 Oct 25.
8
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.修订后的国际分期系统 II 期初诊多发性骨髓瘤患者的长期结局存在异质性。
Haematologica. 2023 May 1;108(5):1374-1384. doi: 10.3324/haematol.2021.280566.
9
Real-world assessment of the treatment patterns and outcomes among patients with multiple myeloma across different risk stratification criteria in the United States: a retrospective cohort study.美国不同风险分层标准下多发性骨髓瘤患者治疗模式和结局的真实世界评估:一项回顾性队列研究
Leuk Lymphoma. 2023 Feb;64(2):388-397. doi: 10.1080/10428194.2022.2140283. Epub 2022 Nov 12.
10
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy.新型药物作为一线治疗时多发性骨髓瘤患者修订后的国际分期系统的综合评估。
Am J Hematol. 2017 Dec;92(12):1280-1286. doi: 10.1002/ajh.24891. Epub 2017 Sep 8.

引用本文的文献

1
A quantum machine learning framework for predicting drug sensitivity in multiple myeloma using proteomic data.一种使用蛋白质组学数据预测多发性骨髓瘤药物敏感性的量子机器学习框架。
Sci Rep. 2025 Jul 22;15(1):26553. doi: 10.1038/s41598-025-06544-2.
2
Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma.联合人工智能驱动的新诊断和复发多发性骨髓瘤事件预测与纵向建模
NPJ Digit Med. 2024 Jul 29;7(1):200. doi: 10.1038/s41746-024-01189-3.
3
The diagnostic value of machine learning for the classification of malignant bone tumor: a systematic evaluation and meta-analysis.

本文引用的文献

1
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients.1号染色体长臂21区异常改善多发性骨髓瘤患者的预后预测——对2596例试验患者的荟萃分析
Haematologica. 2021 Oct 1;106(10):2754-2758. doi: 10.3324/haematol.2021.278888.
2
Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data.基于临床和基因表达数据的机器学习模型在多发性骨髓瘤患者中的生存预测和治疗优化。
Leukemia. 2021 Oct;35(10):2924-2935. doi: 10.1038/s41375-021-01286-2. Epub 2021 May 18.
3
Chromosome 1q21 abnormalities in multiple myeloma.
机器学习对恶性骨肿瘤分类的诊断价值:一项系统评价与Meta分析
Front Oncol. 2023 Sep 7;13:1207175. doi: 10.3389/fonc.2023.1207175. eCollection 2023.
4
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.机器学习改善骨髓纤维化的风险分层:西班牙骨髓纤维化登记处的分析
Hemasphere. 2022 Dec 20;7(1):e818. doi: 10.1097/HS9.0000000000000818. eCollection 2023 Jan.
5
Prognostic Stratification of Multiple Myeloma Using Clinicogenomic Models: Validation and Performance Analysis of the IAC-50 Model.使用临床基因组模型对多发性骨髓瘤进行预后分层:IAC-50模型的验证与性能分析
Hemasphere. 2022 Aug 2;6(8):e760. doi: 10.1097/HS9.0000000000000760. eCollection 2022 Aug.
多发性骨髓瘤中 1q21 染色体异常。
Blood Cancer J. 2021 Apr 29;11(4):83. doi: 10.1038/s41408-021-00474-8.
4
Socioeconomic Status is Globally a Prognostic Factor for Overall Survival of Multiple Myeloma Patients: Synthesis of Studies and Review of the Literature.社会经济地位在全球范围内是多发性骨髓瘤患者总生存期的一个预后因素:研究综述与文献回顾
Mediterr J Hematol Infect Dis. 2021 Jan 1;13(1):e2021006. doi: 10.4084/MJHID.2021.006. eCollection 2021.
5
Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling.利用基因表达谱提高弥漫性大 B 细胞淋巴瘤患者的个体化生存预测。
BMC Cancer. 2020 Oct 21;20(1):1017. doi: 10.1186/s12885-020-07492-y.
6
Machine learning can identify newly diagnosed patients with CLL at high risk of infection.机器学习可以识别新诊断出的 CLL 患者中感染风险较高的患者。
Nat Commun. 2020 Jan 17;11(1):363. doi: 10.1038/s41467-019-14225-8.
7
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.硼替佐米、来那度胺和地塞米松作为多发性骨髓瘤自体移植前的诱导治疗。
Blood. 2019 Oct 17;134(16):1337-1345. doi: 10.1182/blood.2019000241.
8
Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.多发性骨髓瘤患者细胞遗传学预后指数的建立与验证:对生存的预测作用。
J Clin Oncol. 2019 Jul 1;37(19):1657-1665. doi: 10.1200/JCO.18.00776. Epub 2019 May 15.
9
Extramedullary disease in multiple myeloma - controversies and future directions.多发性骨髓瘤中的髓外疾病——争议与未来方向。
Blood Rev. 2019 Jul;36:32-39. doi: 10.1016/j.blre.2019.04.002. Epub 2019 Apr 13.
10
Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by Use of Machine Learning and Nationwide Lymphoma Registries: A Nordic Lymphoma Group Study.利用机器学习和全国淋巴瘤登记系统优化弥漫性大B细胞淋巴瘤的预后预测:北欧淋巴瘤组研究
JCO Clin Cancer Inform. 2018 Dec;2:1-13. doi: 10.1200/CCI.18.00025.